Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

894
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

865
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

329
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

305
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARS-CoV-2-infected cardiomyocytes exhibit upregulated necroptosis, but no evidence of mitochondrial permeability transition.

Journal of molecular and cellular cardiology plus·2026
Same author

Pregnancy-Associated Cardiomyopathy in a Late-Diagnosed Partial Hydatidiform Mole: A Case Report.

Case reports in obstetrics and gynecology·2025
Same author

Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation.

International journal of cardiology·2024
Same author

Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.

Herz·2022
Same author

Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Clinical research in cardiology : official journal of the German Cardiac Society·2021
Same author

[Short version of the 2nd edition of the German-Austrian S3 guidelines "Cardiogenic shock complicating myocardial infarction-Diagnosis, monitoring and treatment"].

Der Anaesthesist·2020

Related Experiment Video

Updated: Jan 29, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Key inflammatory mechanisms underlying heart failure.

C Riehle1, J Bauersachs2

  • 1Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Herz
|February 5, 2019
PubMed
Summary

Cardiac inflammation is key in heart failure development and repair. Targeting inflammation offers potential therapeutic strategies for heart failure, particularly heart failure with preserved ejection fraction (HFpEF).

Keywords:
Cardiac failureCytokinesImmune systemInflammationMyocardial infarction

More Related Videos

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection
05:10

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection

Published on: August 20, 2007

6.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Experiment Videos

Last Updated: Jan 29, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection
05:10

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection

Published on: August 20, 2007

6.4K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Inflammation is central to heart failure pathogenesis, especially in heart failure with preserved ejection fraction (HFpEF).
  • The inflammatory response mediates regenerative processes after acute myocardial injury.
  • Understanding cardiac inflammation's dual role (beneficial/detrimental) is crucial.

Purpose of the Study:

  • To review key inflammatory mechanisms in heart failure pathogenesis.
  • To explore the therapeutic potential of modulating cardiac inflammation.

Main Methods:

  • Literature review of recent human and animal studies.
  • Analysis of underlying mechanisms of inflammatory adaptations in the heart.

Main Results:

  • Inflammation has context-dependent effects on heart failure, influenced by extent, location, and duration.
  • Numerous clinical trials have investigated cardiac inflammation as a therapeutic target.

Conclusions:

  • Modulating cardiac inflammation presents a promising therapeutic avenue for heart failure.
  • Further research into specific inflammatory pathways is warranted for targeted treatments.